The potentiality of dissolving clots has aroused great interest in fibrinolysin (plasmin) as a therapeutic agent in thromboembolism. In this paper the effects of intravenous administration of purified fibrinolysin in man are reported, with special emphasis upon systemic toxicity and alterations in clotting factors and fibrinolytic activity. This information is necessary for the evaluation of this agent for clinical purposes.
SINCE no adequate methods presently exist for detecting the presence of a "prethrombotic" state, the physician must unfortunately deal with thromboembolic disease when it reaches an overt, symptomatic phase. The most effective therapy at this juncture would include a combination of agents that could ensure both prompt dissolution of existing thrombus and prevention of new thrombosis.
Although heparin has some capacity to accelerate the process of clot dissolution in vivo, sione of the anticoagulant drugs adequately satisfies this combined requirement.'-3 Therefore, much recent effort has been devoted to the development of agents that might dissolve intravascular clot acutely.
The therapeutic feasibility of induced clot lysis was suggested by discovery of the intrinsic fibrinolytic activity of plasma, which resides in the plasminogen-plasmin (profibrinolysin-fibrinolysin) system. It appears likely that this lytic system is constantly functioning within the body to remove unwanted fibrin deposits. 4 Unfortunately this normal mechanism rarely acts with sufficient speed and intensity to prevent the sequelae of extensive occlusion in large vessels. Therefore, various attempts are currently being made to achieve rapid thrombolysis with materials that can acutely enhance the fibrinolytic activity of plasma. The proteolytic enzyme trypsin, the bacterial derivative streptokinase, and certain protein-free bacterial pyrogens have all been utilized to dissolve intravascular thrombi. While trypsin in vitro is both directly fibrinolytic and capable of activating profibrinolysin,5 attempts to achieve clot lysis with intravenous trypsin have met with infrequent success.58 Furthermore, the enzyme has such a broad spectrum of proteolytic action that its intravenous administration may lead to serious depletion of plasma coagulation factors. 6, 8, 9 Streptokinase has no direct fibrinolytic activity. Rather, it serves as an activator of profibrinolysin, either directly or by converting a plasma pro-activator to activator.10, 11 Intravenous streptokinase can produce clot lysis in the experimental animal,12 and doses of sufficient size can considerably increase fibrinolytic activity of human plasma.13-'5 Ullfortunately, a significant portion of the population, by virtue of prior streptococcal infection, may exhibit antistreptokinase activity in the plasma. '6 The presence of such antibodies not only raises the possibility of allergic responses,17 but may also play a role in the inconsistency with which well-tolerated doses of streptokinase enhance plasma fibrinolytic activity. 13-'5 The fibrinolytic potential of the pyrogenic bacterial lipopolysaccharides in vivo has been explored by von Kaulla.18, 1' These materials do not exhibit fibrinolytic activity in vitro. The mechanism by which they induce such activity in vivo is uncertain, but present evidence suggests that they act by releasing plasminogen activators from some endogenous source. Such nonenzymatic activation of the plasma fibrinolytic mechanism is a promising development in the effort to find a satisfactory, clinically useful thrombolytic agent.
While both streptokinase and bacterial pyrogens hold considerable promise as effective thrombolytic materials, their indirect mode of action and dependence upon the supply of plasminogen in the plasma have certain practical and theoretical disadvantages. Therefore, other investigators have explored the possibility that fibrinolysin itself, isolated from the human plasma, might prove a more direct and controllable agent for increasing plasma fibrinolytic activity. This possibility has recently become subject to experimental proof by the development of a highly purified preparation of fibrinolysin suitable for clinieal study.20 21 27 Such preferential action may be related not only to the protein structure of these substances but also to the adsorptive affinity of fibrin for fibrinolysin." 1 Finally, the intravenous infusion of fibrinolysin in animals has been attended by minimal evidence of allergic potential or other toxicity.23' 26 Preliminary reports indicate that the experimental data regarding the value and low toxicity of fibrinolysin may apply to man. 28, 29 Detailed study of the toxicity, duration of action, and dosage-response characteristics of fibrinolysin is important, for experience with plied by the manufacturer initially in vials containing 25,000 "fibrinolytic units" per vial. This labeled unitage was determined by the supplier on the basis of assays employing both fibrin and nonfibrin test substrates. The initial lot of material supplied serves as the "house standard" and was assayed in our laboratory by a technic similar to that described by Loomis and co-workers. 30 Serial dilutions of the standard fibrinolysin material were prepared. To 0.1 ml. of the various fibrinolysin dilutions in a 13-by-100 mm. test tube were added 0.2 ml. of a freshly prepared 1 per cent solution of bovine fibrinogen (Armour) in imidazole buffer (pH 7.2) and 0.2 ml. of human thrombin in imidazole-saline-glycerine buffer solution (containing 4 units of thrombin), and the tube was placed in a water bath at 37 C. At 1 minute after the start of incubation and at 30-second intervals thereafter, the tube was removed from the water bath and tilted gently to the horizontal position. A firm clot formed within the first 15 seconds of incubation. The clot remained firm during tilting for many hours if fibrinolysin was absent. In the presence of fibrinolysin, the clot softened and soon after moved freely down the test tube as it was tilted. This was chosen as the endpoint for "partial lysis." If the incubation period is extended, total lysis of the clot will occur. While there is a close correlation between the time required for partial and total lysis ( fig. 1) Assay of Plasma Fibrinolytic Activity. This assay is identical to that described for establishment of the standard curve, with the exception that 0.4 ml. of the patient's plasma was substituted for the 0.1 ml. of fibrinolysin dilution. Thus, the test system consisted of plasma, fibrinogen, and thrombin.
To establish normal values for the assay, 245 control determinations were made (table 2). In addition, 18 patients were studied serially at 0, 3, 6, and 24 hours following start of an intravenous infusion of 1,000 ml. of 5 per cent dextrose in water (table 2) . Finally, 20 hospitalized patients and 15 normal subjects were studied daily for 5 days (table 2) .
These studies indicate the stability of lysis times by this method in serial samples over a 24-hour period and in daily samples.
On the basis of these control values, the assay was terminated after 30 minutes, and no patient with lysis time above 25 minutes was considered to have significant plasma fibrinolytic activity.
Calculation of increase of fibrinolytic activity was determined by the following formula:
Per cent increase = 100 X (Control lysis time) (Lysis time at x hours) (Control lysis time)
By definition, control lysis time cannot exceed 30 minutes.
During the investigation, all lysis times were determined in duplicate and the mean of the 2 was taken as the lysis time. The determinations showed a high degree of reproducibility (table 3). As might be expected, the difference between duplicate determinations tended to increase with longer times except that with a lysis time of 30 minutes or more, a repeat determination gave very similar results, indicating minimal or absent fibrinolytic activity. fig. 7) .
While the incidence of enhanced fibrinolytic activity was equally distributed among the 3 groups at 3 hours, groups II and III showed a higher incidence than group I at 6 hours. At 24 hours, group III showed an incidence of activity significantly greater than the other 2 groups.
The intensity of fibrinolytic activity also Electrocardiographic Changes. Electrocardiographic abnormalities appeared after infusion in 2 patients. A 79-year-old woman with arteriosclerotic heart disease and congestive heart failure developed atrial fibrillation 10 hours after infusion, and a 23-year-old man with deep iliofemoral thrombophlebitis developed transient T-wave changes 6 hours after infusion. Both of these changes occurred near the peak of a febrile reaction.
Urinalysis. No significant changes in urinary sediment followed fibrinolysin infusion. In 12 instances, mild proteinuria was noted 24 hours after infusion, but it cleared by 48 hours. All patients with proteinuria had had febrile reactions.
Miscellaneous Observations. Nausea or chills accompanied approximately one third of the febrile reactions. Two patients vomited. Two instances of apparent allergic skin reaction developed, both on the third day after infusion. One patient developed a hot, erythematous, pruritic reaction at the site of infusion, and the second patient developed a pruritic macular eruption over the extremities and the lower trunk, in addition to a similar but less severe reaction at the infusion site. Both reactions responded to local and antihistaminic therapy within 72 hours. In both cases a moderate fever (100 to 101 F.) developed and an erythematous spot appeared at the site of an intradermal fibrinolysin skin test originally recorded as negative. In 1 patient, a strong allergic history was present. In neither of these cases had subcutaneous infiltration of fibrinolysin occurred.
Subcutaneous infiltration of 5 to 20,000 F. U. inadvertently occurred in 7 patients. No adverse effects were noted other than what might be expected to follow infiltration of comparable amounts of dextrose solution.
Two patients developed unexplained episodes of epigastric pain near the peak of febrile reactions to infusion. The episodes were promptly terminated by meperidine and did not recur. Investigation revealed no cause for the pain in either case.
DIscussIoN
Significant toxicity of intravenous fibrinolysin in man, at the dosage levels employed in this study, appears limited to its pyrogenic potential. The etiology of this pyrogenicity has not yet been defined. Three explanations The effeet of fibrinolysiii upon the huimnai (oagulative process was one of the focal poiiits of this study. The animal investigations of Cliffton et al.23 2' anld Amibrus aild Baek 4' have indicated that a rather wide range of fibriiiolysin dosage will produce sigiificant enhanceneiit of plasmna fibritmolyti( activity wvithout compromise of the coagulation mechanism. In the doses eniployed ill the )reseiit study, fibriniolysin iimfusioii ill humlan subjects caused mimiinial aberration of coagulation factors. While fibriiiolysin undoubtedly s subject to the pharmacologic rule of wide illdividual variation in, response, a considerable margin of safety appears to exist ill man between dosages that significantly enhaiice plasma fibrinolytic activity aiid those that ilmay lead to clinically important impairmeit of the coagulative process.
The laboratory measuremients iii(licatillg that iio gross disturbance of coagulative process followed fibrinolysin admuinistration correlated well with the clinical observation that no hemorrhagie phenomena occurred in ai iy patient, including 29 simultanieouly receiving coumarii-indaimdioine drugs or heparin. These observations are ini agreemient with the animial and humani experience of Clifftoti and Ambrus, who noted that bleeding comiplicated pllasa infusion omily when excessive (loses were given or local vascular lesionis existed during periodls of high lytic activity.
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undue influence upon coagulation probably reflects several independent influences. One factor involved is the capacity of the organism for rapid replacement of depleted components of plasma protein. Absence of depression of a factor cannot be interpreted as absence of destruction in vivo, but it may indicate that restorative mechanisms are able to keep pace with the proteolytic activities of fibrinolysin. The rapidity of fibrinolysin infusion and concentration of the administered solution also may exert a significant influence. While data included here deal with infusions given over 2 hours or more, isolated observations have suggested that rapid infusions of fibrinolysin are accompanied by more profound, though transient, declines in certain factors, especially fibrinogen.
Another circumstance that may limit the degree to which fibrinolysin effects plasma proteins is the apparent preferential action of this enzyme upon fibrin.27 Such preference is probably related not only to the specific protein linkages split by fibrinolysin, but also to the known adsorptive affinity of fibrin for plasma.4 11 Such adsorption would tend to concentrate fibrinolysin activity upon intravascular fibrin. In addition, there is in vitro evidence indicating that inhibition or destruction of plasmin occurs more rapidly when suitable substances are not supplied, a chain of events that would also tend to limit the attack of fibrinolysin to fibrin.37 38 Although the dosage of fibrinolysin used in this study produced no major coagulation defects, serious disturbances may arise if higher doses are employed. Back Such enzymatie assays possess several deficiencies. Variable degrees of " nonfibrinolytie'' esterase activity may be present iii plasma, and its contribution to over-all esterase activity may be difficult to establish. Furthermore, the validity of using a synthetic substrate to replace fibrin in any assay for fibrinolytic activity is subject to question, since the strong affinity of fibrinolysin for fibrin itself may play a significant role in determining the duration and intensity of such activity.
Thus, it appears likely that the esterase and fibrinolytic potencies of plasma may not b)e parallel phenomena. We continue to prefer the fibrinolytic assay described here as the method which yields information of greatest clinical utility.
Despite 
